Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years --
-- Additional $100 million to $120 million in potential royalty revenue estimated to be received by Xencor, based on consensus sales forecasts --
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor's Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering the Xtend Fc domain.
Xencor now anticipates receiving low-single digit royalties on net sales of Ultomiris® (ravulizumab-cwvz), an anti-C5 antibody engineered with a licensed Xtend Fc domain, into December 2028 in the United States. Ultomiris is a drug being developed and commercialized by Alexion Pharmaceuticals, Inc., and is a registered trademark of Alexion. Xencor has also previously secured regulatory extensions of exclusivity in several EU countries, Japan and Australia.
"Xencor's Xtend antibody half-life extension technology is one of several modular XmAb Fc domains that power Xencor's XmAb medicines and drug candidates across internal and partner portfolios," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Importantly, this patent term extension also extends the U.S. royalty term for Ultomiris by approximately three years. We anticipate the resulting additional revenue will support our internal pipeline as it advances into later stages of clinical development and will drive further innovation across our portfolio, continuing to fuel the cycle of value creation that has been central to our strategy."
In 2023, OMERS, one of Canada's largest defined benefit pension plans, acquired royalties due to Xencor on global Ultomiris sales subject to annual caps beginning in 2026. For potential sales related to Ultomiris occurring between 2026 and 2028, OMERS is entitled to receive up to $35 million annually with excess reverting to Xencor. For the nine-month period ending September 30, 2025, Xencor recognized non-cash royalty revenue of $51.0 million. Based upon consensus sales forecasts of Ultomiris, Xencor estimates recognizing potential royalty revenue in excess of the caps in the range of $100 million to $120 million in aggregate for the extended patent term through 2028.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "indicates," "supports," and similar terms, or by express or implied discussions relating to Xencor's business, including, but not limited to, statements regarding expectations for future royalty revenues, the quotations from Xencor's president and chief executive officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management, the risk that the fair value of our marketable equity securities will decline and the risks, uncertainties and other factors described under the heading "Risk Factors" in Xencor's annual report on Form 10-K for the year ended December 31, 2024 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251209345770/en/
Charles Liles
[email protected]
(626) 737-8118
For media:
Cassidy McClain
Inizio Evoke
[email protected]
(619) 694-6291